Loading
Life sciences · Journal article
Materials Today Advances · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Cancer remains one of the leading causes of morbidity and mortality worldwide. Despite continuous advances in anticancer therapy, the clinical effectiveness of many anticancer agents is limited by poor aqueous solubility, low oral bioavailability, extensive first-pass metabolism, and drug resistance. Growing interest is therefore being directed toward lipid-based formulations such as self-emulsifying drug delivery systems (SEDDS), which offer several advantages over conventional formulations. Objective This review provides a comprehensive overview of SEDDS, including their composition, rational formulation design (Quality by Design and in silico approaches), classification, preparation methods, marketed products, and key advantages and limitations. This review focuses on SEDDS in oncology, emphasizing recent preclinical studies, pharmacokinetic improvements, and strategies to overcome major limitations of anticancer agents. Conclusion SEDDS represent a promising platform for improving the delivery of poorly soluble anticancer drugs by enhancing their solubility, oral bioavailability, and pharmacokinetic performance. Recent advances in rational formulation design and functionalization further broaden their potential in cancer therapy; however, challenges related to drug loading, stability, scale-up, and regulatory requirements remain important barriers to clinical translation.